Neuroendocrine cervical carcinoma
Conditions
Interventions
Observational group:None
Sponsors
Obstetrics and Gynecology Hospital, Fudan University
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1.The patient was diagnosed with early-stage NECC, which includes pure neuroendocrine carcinoma (such as small cell type, large cell type, small cell mixed with large cell type, and non-specific type), as well as mixed neuroendocrine carcinoma (i.e., the coexistence of other types of cervical cancer, such as squamous cell carcinoma or adenocarcinoma). 2.The patient is 50 years old or younger and has not reached menopause before the surgery. 3.Prior to being recruited into the study, the patient had undergone radical hysterectomy, with or without bilateral salpingo - oophorectomy and/or lymph node assessment surgery. 4.The patient underwent surgery between January 1, 2000 and December 31, 2023. 5.The patient consented to participate in this study voluntarily and was subject to a comprehensive follow-up system.
Exclusion criteria
Exclusion criteria: 1.The pathological diagnosis was typical or atypical carcinoid (low-grade neuroendocrine tumor). 2.The patient was preoperatively diagnosed with locally advanced or advanced NECC (classified as IB3, IIA2, IIB, IIIC1r, IIIC2r, IIIA to IVB stages according to FIGO 2018), and did not undergo surgery. 3.The patient is over 50 years old or has gone through menopause before the operation. 4.The patient who underwent only radical trachelectomy or cervical conization. 5.The patient with concurrent primary malignancy at other site. 6.The patient who voluntarily requested to withdraw from the study or refused follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Follow-up status (including post-treatment adverse reactions, whether regular follow-up examinations were conducted, whether recurrence occurred, time of recurrence, whether death occurred, whether death was due to NECC, and time of death); | — |
Secondary
| Measure | Time frame |
|---|---|
| Chemotherapy details (drug names, dosages, start and end dates);Radiotherapy details (whether radiotherapy was administered, specific regimen);Surgical details (surgical procedure name, surgical approach—laparoscopic/abdominal/robotic, whether ovarian preservation was performed, whether para-aortic lymph node dissection was performed, surgery date, postoperative pathology report);Preoperative / pre-comprehensive treatment biopsy pathology;HPV infection status (whether infected, genotype, whether turned negative after surgery / comprehensive treatment); | — |
Countries
China
Contacts
Public ContactDing Jingxin
Obstetris & Gynecology Hospital of Fudan University
Outcome results
None listed